BDSX Stock Price, Biodesix Inc Quote, Chart

Market Summary

USD1.23+0.01

Delayedas of 30 Apr 2024, 01:09 pm

0.82%

BDSX Stock Price

View Fullscreen

BDSX RSI Chart

BDSX Valuation

Market Cap

118.3M

Price/Earnings (Trailing)

-2.27

Price/Sales (Trailing)

2.41

Price/Free Cashflow

-2.58

BDSX Price/Sales (Trailing)

BDSX Profitability

Return on Equity

-1.1K%

Return on Assets

-52.62%

Free Cashflow Yield

-38.72%

BDSX Fundamentals

BDSX Revenue

Revenue (TTM)

49.1M

Rev. Growth (Yr)

52.68%

Rev. Growth (Qtr)

8.72%

BDSX Earnings

Earnings (TTM)

-52.1M

Earnings Growth (Yr)

55.06%

Earnings Growth (Qtr)

16.53%

Breaking Down BDSX Revenue

52 Week Range

1.032.12

(Low)(High)

Last 7 days

-5.4%

Last 30 days

-14.7%

Last 90 days

-38.7%

Trailing 12 Months

-29.5%

How does BDSX drawdown profile look like?

BDSX Financial Health

Current Ratio

1.19

BDSX Investor Care

Shares Dilution (1Y)

24.32%

Diluted EPS (TTM)

-0.64

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	40.7M	41.6M	44.0M	49.1M
2022	32.2M	31.3M	35.8M	38.2M
2021	69.3M	77.0M	74.3M	54.5M
2020	29.8M	35.1M	40.3M	45.6M
2019	0	0	0	24.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Biodesix Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	watts charles m	acquired	-	-	134,262	-
Feb 12, 2024	vazquez chris	sold	-1,534	1.6647	-922	chief accounting officer
Feb 12, 2024	o'kane kieran	sold	-9,009	1.6647	-5,412	chief commercial officer
Feb 12, 2024	cowie robin harper	sold	-14,481	1.6647	-8,699	cfo, sec'y & treasurer
Feb 12, 2024	pestano gary anthony	sold	-8,360	1.6647	-5,022	chief development officer
Feb 12, 2024	hutton scott	sold	-49,454	1.6647	-29,708	president & ceo
Feb 09, 2024	vazquez chris	sold	-2,064	1.9166	-1,077	chief accounting officer
Feb 09, 2024	pestano gary anthony	sold	-11,235	1.9166	-5,862	chief development officer
Feb 09, 2024	cowie robin harper	sold	-19,465	1.9166	-10,156	cfo, sec'y & treasurer
Feb 09, 2024	o'kane kieran	sold	-12,111	1.9166	-6,319	chief commercial officer

Which funds bought or sold BDSX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	1,000	1,000	-%
Apr 25, 2024	Allworth Financial LP	added	77.84	39,274	142,044	-%
Apr 15, 2024	Legato Capital Management LLC	unchanged	-	-137,067	478,063	0.06%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-20.56	-192,413	1,493,620	-%
Feb 15, 2024	BARCLAYS PLC	new	-	17,000	17,000	-%
Feb 15, 2024	JANE STREET GROUP, LLC	added	63.28	36,331	80,594	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	added	171	112,591	168,029	-%
Feb 14, 2024	CITADEL ADVISORS LLC	reduced	-41.34	-25,462	48,166	-%
Feb 14, 2024	ORACLE INVESTMENT MANAGEMENT INC	added	44.83	42,703	112,128	0.07%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	added	27.33	124,728	421,728	0.01%

Are Funds Buying or Selling BDSX?

Are funds buying BDSX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BDSX

No. of Funds

Unveiling Biodesix Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 09, 2024	kennedy lawrence t. jr	9.1%	10,304,824	SC 13D/A
Apr 09, 2024	strobeck matthew	4.98%	5,672,000	SC 13D/A
Apr 09, 2024	patience john	6.7%	7,659,411	SC 13D/A
Apr 09, 2024	schuler jack w	27.2%	31,038,797	SC 13D/A
Feb 07, 2024	hirschman orin	3.8%	3,408,946	SC 13G/A
Aug 11, 2023	schuler jack w	32.1%	30,787,721	SC 13D/A
Aug 07, 2023	kennedy lawrence t. jr	10.0%	9,582,783	SC 13D/A
Aug 07, 2023	patience john	7.9%	7,536,698	SC 13D/A
Mar 21, 2023	hirschman orin	7.1%	5,568,901	SC 13G
Jan 13, 2023	kennedy lawrence t. jr	12.0%	9,148,889	SC 13D

Recent SEC filings of Biodesix Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 23, 2024	S-1	Initial Public Offering
Apr 16, 2024	PRE 14A	PRE 14A
Apr 09, 2024	SC 13D/A	13D - Major Acquisition
Apr 09, 2024	SC 13D/A	13D - Major Acquisition
Apr 09, 2024	SC 13D/A	13D - Major Acquisition
Apr 09, 2024	SC 13D/A	13D - Major Acquisition
Apr 09, 2024	8-K	Current Report

Peers (Alternatives to Biodesix Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	182.6B	23.7B	-1.16%	4.18%	41.49	7.69	-8.94%	-35.72%
IDXX	42.0B	3.7B	-6.41%	2.68%	49.69	11.47	8.72%	24.44%
A	40.9B	6.7B	-4.07%	3.07%	33.1	6.07	-2.81%	-6.58%
DGX	14.9B	9.3B	4.80%	0.50%	17.63	1.61	-3.29%	6.68%
MEDP	12.3B	2.0B	-0.97%	99.97%	39.25	6.25	25.57%	21.62%
CRL	11.9B	4.1B	-14.34%	22.08%	25.11	2.89	3.86%	-2.39%
NTRA	11.4B	1.1B	2.82%	85.41%	-26.12	10.49	31.99%	20.63%
EXAS	10.7B	2.5B	-14.89%	-8.26%	-52.27	4.27	19.93%	67.26%
MID-CAP
NEOG	2.7B	929.2M	-21.29%	-27.87%	1.7K	2.9	28.93%	111.61%
GH	2.2B	563.9M	-11.83%	-19.37%	-4.62	3.93	25.45%	26.76%
SMALL-CAP
CDNA	424.6M	280.3M	-22.57%	1.36%	-2.23	1.51	-12.89%	-148.37%
ACRS	86.5M	31.2M	-1.61%	-86.28%	-0.98	2.77	5.03%	-1.81%
APDN	65.4M	9.0M	839.02%	296.91%	-9.04	7.27	-53.31%	2.21%
AWH	41.1M	9.2M	7.42%	-36.33%	-2.46	4.49	11.85%	44.12%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Biodesix Inc News

Latest updates

Biodesix Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Revenue	8.7%	14,668	13,491	11,872	9,056	9,607	11,107	10,950	6,548	7,224	6,531	11,885	28,866	27,029	9,193	4,239	5,096	4,519	3,942
Operating Expenses	4.2%	21,538	20,663	22,799	25,429	23,497	21,717	22,576	21,009	18,903	19,622	22,472	34,449	29,682	15,433	9,858	13,518	-	12,970
S&GA Expenses	4.9%	16,251	15,496	16,651	18,989	16,626	15,114	15,235	14,487	13,558	13,607	11,425	11,927	12,064	7,879	6,834	8,080	-	8,212
R&D Expenses	-2.5%	1,889	1,938	2,910	3,251	3,565	2,970	3,361	3,206	2,852	3,293	3,323	3,321	3,105	2,706	2,107	2,900	-	2,359
Interest Expenses	-2.4%	2,329	2,386	2,430	2,391	2,550	3,039	1,346	1,137	1,496	1,546	815	651	705	2,658	2,784	1,457	-	706
Net Income	16.5%	-9,139	-10,949	-13,356	-18,702	-20,338	-13,699	-15,824	-15,586	-13,282	-11,514	-11,402	-6,961	-38,630	-8,845	-8,266	-9,706	-6,525	-9,601
Net Income Margin	26.2%	-1.06*	-1.44*	-1.59*	-1.68*	-1.71*	-1.63*	-1.80*	-1.61*	-0.79*	-0.92*	-0.86*	-0.90*	-	-	-	-	-	-
Free Cashflow	-57.7%	-15,267	-9,680	-5,480	-15,362	-13,878	-11,108	-9,923	-13,361	-10,727	-8,754	809	-11,792	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	14.2%	99.00	87.00	78.00	81.00	93.00	63.00	75.00	62.00	76.00	90.00	102	115	121	47.00	45.00
Current Assets	37.4%	40.00	29.00	25.00	35.00	53.00	24.00	35.00	27.00	44.00	56.00	68.00	81.00	86.00	18.00	13.00
Cash Equivalents	32.5%	26.00	20.00	17.00	25.00	43.00	15.00	29.00	17.00	33.00	48.00	56.00	55.00	62.00	7.00	5.00
Net PPE	9.7%	28.00	25.00	19.00	13.00	6.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	2.00
Goodwill	0%	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	12.00	15.00
Liabilities	7.1%	95.00	88.00	85.00	76.00	72.00	66.00	68.00	54.00	56.00	74.00	76.00	79.00	80.00	108	76.00
Current Liabilities	2.3%	33.00	33.00	28.00	22.00	23.00	37.00	33.00	30.00	29.00	23.00	21.00	16.00	32.00	57.00	23.00
Shareholder's Equity	-	5.00	-	-	5.00	21.00	-	8.00	8.00	20.00	16.00	26.00	36.00	41.00	-	-
Retained Earnings	-2.2%	-419	-410	-399	-386	-367	-347	-333	-317	-301	-288	-277	-265	-258	-257	-227
Additional Paid-In Capital	3.7%	424	409	392	391	388	344	341	325	322	305	303	302	300	3.00	2.00
Shares Outstanding	9.0%	96.00	88.00	79.00	78.00	78.00	37.00	35.00	31.00	31.00	27.00	3.00	27.00	-	-	-
Float	-	-	-	37.00	-	-	-	34.00	-	-	-	197	-	345	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	-220.0%	-12,283	-3,838	937	-7,686	-11,948	-10,331	-9,594	-13,099	-10,197	-7,790	1,090	-11,326	-8,756	-3,770	-4,303	-4,537	-	-
Share Based Compensation	13.3%	1,081	954	1,057	2,281	2,077	1,170	1,368	1,346	1,267	1,386	539	1,752	3,554	100	-	-	-	-
Cashflow From Investing	49.0%	-3,001	-5,883	-6,472	-7,706	-1,987	-815	-380	-352	-641	-1,042	-348	-516	-543	-1,566	-426	-392	-	-
Cashflow From Financing	78.8%	21,728	12,152	-2,330	-2,421	41,848	-2,265	22,133	-2,834	-4,363	396	278	4,951	65,076	9.00	9,626	6,420	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BDSX Income Statement

2023-12-31

Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues	$ 49,087	$ 38,212
Operating expenses:
Direct costs and expenses	13,010	14,154
Research and development	9,988	13,102
Sales, marketing, general and administrative	67,387	61,462
Impairment loss on intangible assets	44	81
Total operating expenses	90,429	88,799
Loss from operations	(41,342)	(50,587)
Other (expense) income:
Interest expense	(9,536)	(8,072)
Loss on extinguishment of liabilities, net		(6,981)
Change in fair value of warrant liability, net	(1,274)	84
Other income , net	6	109
Total other expense	(10,804)	(14,860)
Net loss	$ (52,146)	$ (65,447)
Net loss per share, basic	$ (0.64)	$ (1.55)
Net loss per share, diluted	$ (0.64)	$ (1.55)
Weighted-average shares outstanding, basic	82,113	42,103
Weighted-average shares outstanding, diluted	82,113	42,103

BDSX Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 26,284	$ 43,088
Accounts receivable, net of allowance for doubtful accounts of $65 and $118	7,679	5,065
Other current assets	5,720	5,181
Total current assets	39,683	53,334
Non‑current assets
Property and equipment, net	27,867	5,848
Intangible assets, net	7,911	9,797
Operating lease right-of-use assets	1,745	2,973
Goodwill	15,031	15,031
Other long-term assets	6,859	5,923
Total non‑current assets	59,413	39,572
Total assets	99,096	92,906
Current liabilities
Accounts payable	2,929	1,685
Accrued liabilities	7,710	8,218
Deferred revenue	324	962
Current portion of operating lease liabilities	252	1,543
Current portion of contingent consideration	21,857	10,341
Current portion of notes payable	51	49
Other current liabilities	293	41
Total current liabilities	33,416	22,839
Non‑current liabilities
Long-term notes payable, net of current portion	35,225	25,004
Long-term operating lease liabilities	25,163	5,254
Contingent consideration		18,645
Other long-term liabilities	712	558
Total non‑current liabilities	61,100	49,461
Total liabilities	94,516	72,300
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.001 par value, 5,000,000 authorized; 0 (2023 and 2022) issued and outstanding
Common stock, $0.001 par value, 200,000,000 authorized; 96,235,883 (2023) and 77,614,358 (2022) shares issued and outstanding	96	78
Additional paid‑in capital	424,050	387,948
Accumulated deficit	(419,566)	(367,420)
Total stockholders' equity	4,580	20,606
Total liabilities and stockholders' equity	$ 99,096	$ 92,906

About Biodesix Inc

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a blood-based NGS. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.

CEO	Mr. Scott Hutton
WEBSITE	biodesix.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	245

Biodesix Inc Frequently Asked Questions

What is the ticker symbol for Biodesix Inc? What does BDSX stand for in stocks?

BDSX is the stock ticker symbol of Biodesix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biodesix Inc (BDSX)?

As of Mon Apr 29 2024, market cap of Biodesix Inc is 118.27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BDSX stock?

You can check BDSX's fair value in chart for subscribers.

What is the fair value of BDSX stock?

You can check BDSX's fair value in chart for subscribers. The fair value of Biodesix Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biodesix Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BDSX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biodesix Inc a good stock to buy?

The fair value guage provides a quick view whether BDSX is over valued or under valued. Whether Biodesix Inc is cheap or expensive depends on the assumptions which impact Biodesix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BDSX.

What is Biodesix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, BDSX's PE ratio (Price to Earnings) is -2.27 and Price to Sales (PS) ratio is 2.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BDSX PE ratio will change depending on the future growth rate expectations of investors.